Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immunome (IMNM) Accumulated Expenses (2023 - 2025)

Immunome (IMNM) has disclosed Accumulated Expenses for 3 consecutive years, with $11.5 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Accumulated Expenses fell 65.26% year-over-year to $11.5 million, compared with a TTM value of $11.5 million through Dec 2025, down 65.26%, and an annual FY2025 reading of $11.5 million, down 65.26% over the prior year.
  • Accumulated Expenses was $11.5 million for Q4 2025 at Immunome, up from $7.2 million in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $33.2 million in Q4 2024 and bottomed at $827000.0 in Q1 2023.
  • Average Accumulated Expenses over 3 years is $10.9 million, with a median of $8.0 million recorded in 2023.
  • The sharpest move saw Accumulated Expenses surged 1211.25% in 2024, then plummeted 65.26% in 2025.
  • Year by year, Accumulated Expenses stood at $8.0 million in 2023, then soared by 313.42% to $33.2 million in 2024, then tumbled by 65.26% to $11.5 million in 2025.
  • Business Quant data shows Accumulated Expenses for IMNM at $11.5 million in Q4 2025, $7.2 million in Q3 2025, and $18.2 million in Q2 2025.